NFKB1 and cancer: As the malfunction of DUBs such as CYLD, A20, and OTUD7B has been observed in various cancers and greatly contributes to constitutive NF-κB signalling activation, identifying the key factor(s) that upregulate and/or activate these DUBs might facilitate the identification of novel targets for therapeutic intervention.